CD274 gene encodes programmed death-ligand 1 (PD-L1) protein, also known as B7 homolog 1 (B7-H1), which is a crucial hallmark for highly proliferation cells including cancer cells. PD-1 and PD-L1 interaction is assumed as a negative regulator for immune response which can inhibit the T cell growth and cytokine secretion and supports tumor cells evasion from immune system. therefore, PD-L1 could be assumed as a candidate target for immune-therapy. The predicted structure of PD-L1 indicates (Gly4Ser) 3 linker-based chains links. In that line, different simulation softwares applied to explore the structure of granzyme B (GrB), a serine protease in cytotoxic lymphocytes granules as an apoptosis mediator, was attached to its specific antibody structure (atezolizumab) via an adaptor sequence. Evaluation of accuracy, energy minimization and characterization of biological properties of the final processed structure were performed and our computational outcomes indicated that the employed method for structure prediction has been successfully managed to design the immunotoxin structure. It is necessary to mention that, the precise and accurate design of the immune-therapeutic agents against cancer cells can be confirmed by employment of in-silico approaches. Consequently, based on this approach we could introduce a capable immunotoxin which specifically targeting PD-L1 in an accurate orientation and initiates cancer cell destruction by its toxin domain.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Availability of data and materials
Data presented in this manuscript is available upon request.
Protein data bank
Oxford Protein Informatics Group
Akbari B, Farajnia S, Ahdi Khosroshahi S, Safari F, Yousefi M, Dariushnejad H et al (2017) Immunotoxins in cancer therapy: review and update. Int Rev Immunol 36(4):207–219
Becker OM, MacKerell AD, Roux B, Watanabe M (2001) Computational biochemistry and biophysics. Marcel Dekker, New York
Boivin WA, Cooper DM, Hiebert PR, Granville DJ (2009) Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma. Lab Invest 89(11):1195
Brahmer JR, Tykodi SS, Chow LQ, Hwu W-J, Topalian SL, Hwu P et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455–2465
Chowdhury D, Lieberman J (2008) Death by a thousand cuts: granzyme pathways of programmed cell death. Annu Rev Immunol 26:389–420
Estébanez-Perpiñá E, Fuentes-Prior P, Belorgey D, Braun M, Kiefersauer R, Maskos K et al (2000) Crystal structure of the caspase activator human granzyme B, a proteinase highly specific for an Asp-P1 residue. Biol Chem 381(12):1203–1214
Fiser A, Šali A (2003) Modeller: generation and refinement of homology-based protein structure models. Methods in enzymology, vol 374. Elsevier, Amsterdam, pp 461–491
Ganji M, Khalili S, Mard-Soltani M, Khalesi B, Karkhah A, Amani J (2020) A precisely designed immunotoxin against VCAM1 consisting of a humanized antibody variable domain fused to granzyme: an in silico approach. Int J Pept Res Ther 26(1):129–137
Hehmann-Titt G, Schiffer S, Berges N, Melmer G, Barth S (2013) Improving the therapeutic potential of human granzyme B for targeted cancer therapy. Antibodies 2(1):19–49
Hengartner MO (2000) The biochemistry of apoptosis. Nature 407(6805):770
Hiebert PR, Granville DJ (2012) Granzyme B in injury, inflammation, and repair. Trends Mol Med 18(12):732–741
Kägi D, Ledermann B, Bürki K, Seiler P, Odermatt B, Olsen KJ et al (1994) Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369(6475):31
Karwacz K, Bricogne C, MacDonald D, Arce F, Bennett CL, Collins M et al (2011) PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Mol Med 3(10):581–592
Khalili S, Rasaee MJ, Mousavi SL, Amani J, Jahangiri A, Borna H (2017a) In silico prediction and in vitro verification of a novel multi-epitope antigen for HBV detection. Mol Genet Microbiol Virol 32(4):230–240
Khalili S, Zakeri A, Hashemi ZS, Masoumikarimi M, Manesh MRR, Shariatifar N et al (2017b) Structural analyses of the interactions between the thyme active ingredients and human serum albumin. Turk J Biochem 42(4):459–467
Khalili S, Rasaee MJ, Bamdad T, Mard-Soltani M, Ghalehni MA, Jahangiri A et al (2018) A novel molecular design for a hybrid phage-DNA construct against DKK1. Mol Biotechnol 60(11):833–842
Kortt AA, Dolezal O, Power BE, Hudson PJ (2001) Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol Eng 18(3):95–108
Kreitman RJ (2003) Immunotoxins for targeted cancer therapy. Chimeric toxins. CRC Press, Boca Raton, pp 219–237
Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I et al (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2(3):261–268
Madhumathi J, Devilakshmi S, Sridevi S, Verma RS (2016) Immunotoxin therapy for hematologic malignancies: where are we heading? Drug Discov Today 21(2):325–332
Mohammadpour H, Du W, O’Neill R, Khalili S, Qiu J, Repasky EA et al (2018) Host-derived serine protease inhibitor 6 provides granzyme B-independent protection of intestinal epithelial cells in murine graft-versus-host disease. Biol Blood Marrow Transplant 24(12):2397–2408
Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9(10):767
Payandeh Z, Rajabibazl M, Mortazavi Y, Rahimpour A, Taromchi AH (2018) Ofatumumab monoclonal antibody affinity maturation through in silico modeling. Iran Biomed J 22(3):180
Payandeh Z, Rajabibazl M, Mortazavi Y, Rahimpour A, Taromchi AH, Dastmalchi S (2019) Affinity maturation and characterization of the ofatumumab monoclonal antibody. J Cell Biochem 120(1):940–950
Rezaeeyan H, Hassani SN, Barati M, Shahjahani M, Saki N (2017) PD-1/PD-L1 as a prognostic factor in leukemia. J Hematopathol 10(1):17–24
Saito Y, Kondo H, Hojo Y (2011) Granzyme B as a novel factor involved in cardiovascular diseases. J Cardiol 57(2):141–147
Santini FC, Rudin CM (2017) Atezolizumab for the treatment of non-small cell lung cancer. Expert Rev Clin Pharmacol 10(9):935–945
Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ (2007) The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 8(3):239
Wang X, Teng F, Kong L, Yu J (2016) PD-L1 expression in human cancers and its association with clinical outcomes. OncoTargets Ther 9:5023
Waugh SM, Harris JL, Fletterick R, Craik CS (2000) The structure of the pro-apoptotic protease granzyme B reveals the molecular determinants of its specificity. Nat Struct Mol Biol 7(9):762
Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B et al (2015) Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1. Structure 23(12):2341–2348
Zhang F, Qi X, Wang X, Wei D, Wu J, Feng L et al (2017) Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab. Oncotarget 8(52):90215
The authors wish to thank Immunology Research Center, Tabriz-Iran and Shahid Sadoughi University of Medical Science, Yazd, Iran for their support by unrestricted free access to the web site for data collection.
This work was financially supported by grants from the Iran National Science Foundation (INSF), Iran (project no. 97021150) and Tabriz University of Medical Sciences, Tabriz, Iran (project no. 61892). We gratefully acknowledge them for their contribution to this study.
Conflict of interest
All authors declare no potential conflicts of interest.
Ethics approval and consent to participate
This article does not contain any studies with human participants or animals performed by any of the authors.
Consent for publication
All authors have read and approved the final version of the manuscript.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Below is the link to the electronic supplementary material.
About this article
Cite this article
Sefid, F., Payandeh, Z., Azamirad, G. et al. Atezolizumab and granzyme B as immunotoxin against PD-L1 antigen; an insilico study. In Silico Pharmacol. 9, 20 (2021). https://doi.org/10.1007/s40203-021-00076-z
- Granzyme B